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Background and Aim of the Study: The coronavirus disease 2019 (COVID‐19)
pandemic has put an enormous strain on healthcare systems and intensive care unit
(ICU) capacity, leading to suspension of most elective procedures, including trans-
catheter aortic valve replacement (TAVR). However, deferment of TAVR is asso-
ciated with significant wait‐time mortality in patients with severe aortic valve
stenosis. Conversely, there is currently no data available regarding the safety and
feasibility of a continued TAVR program during this unprecedented crisis. The aim
of this study is to evaluate the safety and feasibility of patients undergoing TAVR
during the COVID‐19 pandemic in our center, with specific emphasis on COVID‐19
related outcomes.
Methods: All patients who underwent TAVR in our center between February 27,
2020, and June 30, 2020, were evaluated. Clinical outcomes were described in
terms of Valve Academic Research Consortium 2 definitions. Patient follow‐up was
done by chart review and telephone survey.
Results: A total of 71 patients have undergone TAVR during the study period.
Median age was 80 years, 63% were men, and 25% were inpatients. Procedural
success was 99%. After TAVR, 30% involved admission to the ICU, and 94% were
ultimately discharged to the cardiac care unit on the same day. Two patients (3%)
had confirmed COVID‐19 a few days after TAVR, and both died of COVID‐19
pneumonia within 2 weeks after hospital discharge.
Conclusions: A continued TAVR program during the COVID‐19 pandemic is feasible
despite limited hospital resources. However, COVID‐19 related mortality after
TAVR is of concern.
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1 | INTRODUCTION
The coronavirus disease 2019 (COVID‐19) pandemic1 has put an
enormous strain on existing healthcare systems and resources world-
wide, leading to the deferment of most elective procedures.2,3 This
especially affects patients with severe aortic valve stenosis (AS)
awaiting transcatheter aortic valve replacement (TAVR), a recognized
vulnerable population with established cardiovascular disease and im-
portant comorbidities. There is general consensus that the deferment of
these potentially life‐saving procedures is associated with dangers of
sudden cardiac death or irreversible cardiac deterioration. For example,
it has been reported that there are important wait‐time mortality risks
of 23.3% and 27.5%, respectively at 6‐ and 12‐month awaiting TAVR.4
The American College of Cardiology (ACC) and Society of Cardiac
Angiography and Interventions (SCAI) have recently published a con-
sensus statement regarding triage considerations for patients referred
for structural heart disease intervention during the COVID‐19 crisis,
including when to perform TAVR for severe symptomatic AS.5 How-
ever, the risks of adverse events caused by postponement of these
interventions should be balanced against the additional COVID‐19
related dangers of performing (high‐risk) cardiovascular interventions
during this global crisis. Unfortunately, there is currently a paucity of
data to properly estimate the additional hazards of TAVR during the
COVID‐19 pandemic, especially regarding the risks of COVID‐19
transmission just before or after the intervention (either through
healthcare workers, visitors, or other patients), but also regarding
COVID‐19 related morbidity and mortality. Therefore, we performed
the current study to evaluate the feasibility and safety of a continued
TAVR program during the COVID‐19 pandemic in the Netherlands,
evaluating early clinical results with specific emphasis on COVID‐19
related outcomes.
2 | MATERIALS AND METHODS
We conducted a single‐institutional cohort study evaluating all pa-
tients who underwent TAVR in our center for various urgency in-
dications (Table 1) during the COVID‐19 period in The Netherlands.
The local Medical Research Ethics Committee provided a waiver
since the study does not require an ethical review. Informed consent
was also waived by the aforementioned Committee. The study was
conducted in accordance with the principles of ICH Good Clinical
Practice, applicable privacy requirements, and guiding principles of
the Declaration of Helsinki. The study period began on February 27,
2020, with the identification of the first COVID‐19 patient in the
Netherlands, and ended June 30, 2020. Up until September 17, 2020,
more than 84,000 patients have been tested positive for COVID‐19
in the Netherlands with a total population of 17 million inhabitants,
necessitating more than 12,300 hospital admissions and leading to
more than 6200 deaths.6 In our hospital, we have admitted more
than 330 patients with COVID‐19. At the peak of the pandemic, we
had 48 patients admitted on the COVID‐ 19 ward and 41 patients on
the intensive care unit (ICU) on a single day. There is a healthcare
worker COVID‐19 screening program where personnel can be tested
on a daily basis in case of suspect symptoms.7 Just over 240 hospital
employees have tested positive at our institution and most have
returned to work. Most common risk factor for COVID‐19 was
outside the hospital setting (ski trip, carnival festivities, or a house-
hold member positive).
2.1 | Patient triage
With progression of the COVID‐19 crisis and the increasing
COVID‐19 caseload on the ICU, our center started with deferral of
all nonurgent procedures on March 16, 2020. From that time, all
patients on the TAVR waiting list were triaged on a daily basis by a
single TAVR cardiologist (MvW), based on an urgency classification
system categorized into three levels (Table 1): Levels 1, 2, and 3,
indicating TAVR to be performed preferably within 1 week, 1 month,
or 3 months, respectively. Level of urgency was mainly determined
by symptom severity and echocardiographic features (Table 1).
Our classification is largely comparable with the later published
ACC/SCAI consensus statement.5 The consenting process to
undergo a TAVR procedure during the COVID‐19 pandemic
did not differ significantly from the one in the pre‐COVID‐19 era.
TABLE 1 Urgency categories for patients with severe aortic valve stenosis awaiting transcatheter aortic valve replacement
Timing intervention <1 Week <1 Month <3 Months
Indication Life‐threatening in case of deferral of
procedure
Potentially life‐threatening or negatively
impacting prognosis in case of deferral
of procedure for more than 1 month
Limited impact on prognosis in
case of deferral of procedure
for more than 1 month
Symptomatology Severely symptomatic Moderately symptomatic Mildly symptomatic
Complaints Heart failure requiring hospitalization,
severe orthopnea
Syncope due to AS, dizziness NYHA I–II, anginal complaints
Echocardiography Critical AS (AVA <0.6 cm2 and/or mean
gradient >60mmHg) or severe AS
(AVA <1.0 cm2 and/or mean gradient
>40mmHg)
Critical AS (AVA <0.6 cm2 and/or mean
gradient >60mmHg) or severe AS
(AVA <1.0 cm2 and/or mean gradient
>40mmHg)
Severe AS (AVA <1.0 cm2 and/or
mean gradient >40mmHg)
Abbreviations: AS, aortic valve stenosis; AVA, aortic valve area.
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However, the risk of a possible COVID‐19 infection was well
weighed against the risk of postponing the TAVR procedure. In the
pre‐COVID‐19 era our hospital performed on average five TAVR
procedures per week, divided over two working days. From the
beginning of this pandemic, along with the progressive restriction
on hospital resources, our hospital strived to perform one TAVR
procedure on each regular working day. By spreading the TAVR
procedures, the burden on anesthesia personnel, coronary care
unit and ICUs was reduced.
2.2 | Periprocedural COVID‐19 screening
and management
All patients were screened for COVID‐19 symptoms and contacts
with COVID‐19 suspected individuals. For outpatients, this was
performed by telephone survey. From April 6, 2020, routine pre-
operative COVID‐19 screening with polymerase chain reaction
(PCR) testing was commenced in our institution for high complex
surgical procedures. For patients planned for TAVR under general
anesthesia, as well as procedures planned under conscious sedation
but with a high risk for conversion to general anesthesia, PCR testing
was performed less than 48 h before procedure. In patients planned
for TAVR under conscious sedation without high risk for conversion
and without suspicion of COVID‐19, no PCR testing was performed.
TAVR was deferred for all patients with possible COVID‐19 symp-
toms and/or a positive PCR.
TAVR was performed according to routine protocol. Procedures
were performed in a hybrid catheterization laboratory with a stan-
dard operating team consisting of an
interventional cardiologist, cardiothoracic surgeon, imaging car-
diologist, and anesthesiologist. When endotracheal intubation was
performed, only the anesthesiologist and necessary (anesthesia)
personnel were present in the room, dressed in isolation gowns,
FFP‐2 masks and face shields. During the TAVR procedure, routine
universal precautions and personal protective equipment usage were
followed, including standard surgical masks. After the procedure,
patients were transferred to the cardiac care unit (CCU), unless
admission to the ICU was indicated. During the study period,
patients were transferred to a separate, newly created non‐
COVID‐19 ICU when indicated. During the postprocedural period in
the ICU, routine protective measures were followed, including plastic
nonreusable gowns and nonsterile gloves for all personnel. There
was no personnel interchange during work shifts between the
non‐COVID‐19 ICU and the specific COVID‐19 ICUs.
Patients were routinely transferred 1 day after TAVR to their
referring hospital for further rehabilitation. Both the TAVR protocol
and our study protocol did not change over time. Since the TAVR
population, in general, is an elderly, vulnerable population, most
patients who underwent a TAVR procedure presumably stayed
mostly at home during the first postoperative period to prevent a
possible COVID‐19 infection. However, we have no data available
on this.
2.3 | Data collection and follow‐up
Data collection was performed by chart review from our institution
as well as the referring center. In addition, all patients underwent
telephone follow‐up at least 2 weeks after definitive hospital dis-
charge. Clinical endpoints were prospectively collected according to
the updated Valve Academic Research Consortium 2 (VARC‐2)
criteria.8
2.4 | Statistical analysis
Categorical variables are presented as numbers with percentages
and frequencies. Continuous variables are presented as median with
interquartile range (IQR). Descriptive statistics were performed
using IBM SPSS Statistics software version 25.0 (IBM Corp).
3 | RESULTS
During the study period, 71 consecutive TAVR procedures were
performed (Table 2). Median age in this cohort was 80 years (74–84)
and 63% were men. All patients were referred for TAVR due to
symptomatic, severe AS, except for one case who was referred be-
cause of severe aortic regurgitation. Before TAVR, patients had
median New York Heart Association (NYHA) functional Class II, with
28 patients (39%) being in NYHA Class III–IV. Median left ventricular
ejection fraction (LVEF) was 55%. A total of 18 patients (25%) were
inpatients, admitted with heart failure or syncope due to severe AS.
The majority of patients were outpatients who were highly symp-
tomatic with either severe or critical AS (Table 2).
Conscious sedation was planned in 43 patients (61%), of which
one patient required conversion to general anesthesia due to
failure of the vascular closure device, necessitating surgical repair
of the femoral artery. Other VARC‐2‐defined outcomes (Table 3)
included 6 patients (8%) requiring a permanent pacemaker im-
plantation due to conduction disturbances, 8 patients (11%) with
either a minor or major vascular complication, 8 patients (11%)
with either a minor or major bleeding and 1 patient (1%) with
conversion to open surgery due to luxation of the device in the
ascending aorta. There was one procedural death: the patient had
severe left ventricular dysfunction at the start of the procedure,
which was significantly deteriorated when compared to a trans-
thoracic echocardiogram 5 weeks earlier. The patient progressed
to sustained ventricular tachycardia and persistent cardiogenic
shock during placement of the valve prosthesis, followed by
unsuccessful cardiopulmonary resuscitation.
Of the remaining 70 patients, 21 involved admission to the ICU,
mainly for postanesthesia recovery. Of these 21 patients, 18 were
discharged to the CCU on the same day.
Patients were discharged to their referring center after a median
stay of two days in our institution. In their referring center, median
hospital stay was 3 days, resulting in a median total hospital stay of
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Age, years 80 (74–84)
Male gender, n (%) 45 (63)
Body mass index (BMI), kg/m2 27 (24–30)
Obesity (BMI >30), n (%) 17 (24)
Current smoker, n (%) 4 (6)
Medical history
Hypertension, n (%) 49 (69)
Diabetes mellitus, n (%) 26 (37)
Coronary artery disease, n (%) 49 (69)
Previous myocardial infarction, n (%) 16 (23)
Previous percutaneous coronary intervention,
n (%)
32 (45)
Previous cardiac surgery, n (%) 16 (23)
Peripheral artery disease, n (%) 15 (21)
Previous stroke/TIA, n (%) 14 (20)
Creatinine >2mg/dl, n (%) 5 (7)
MDRD‐GFR, ml/min 63 (50–76)
Liver disease, n (%) 1 (1)
Current/previous malignancy, n (%) 16 (23)
COPD, n (%) 15 (21)
Atrial fibrillation, n (%) 27 (38)
Prior pacemaker/ICD implantation, n (%) 1 (1)
EuroSCORE II 2.4 (1.5–4.4)
EuroSCORE, logistic 11.7 (7.0–22.9)
NYHA class 2 (2–3)
NYHA Class III/IV, n (%) 28 (39)
Preoperative screening by geriatrist, n (%) 49 (69)
Frailty
Not frail, n (%) 49 (69)
Mildly frail, n (%) 18 (25)
Moderately frail, n (%) 4 (6)
Urgency level of TAVR procedure
Urgency 1 (TAVR <1 week), n (%) 17 (24)
Urgency 2 (TAVR <1 month), n (%) 30 (42)
Urgency 3 (TAVR <3 months), n (%) 24 (34)
Inpatient/outpatients, n (%) 18/53 (25/75)
Echocardiographic variables
Left ventricular ejection fraction, % 55 (45–60)
Aortic valve area, cm2 0.8 (0.6–0.9)
Mean gradient, mmHg 40 (30–49)
Moderate or severe mitral regurgitation, n (%) 9 (13)
Note: Data are presented as median with interquartile range, or as
number (%).
Abbreviations: COPD, chronic obstructive pulmonary disease;
ICD, implantable cardioverter defibrillator; MDRD‐GFR, modification of
diet in renal disease—glomerular filtration rate; NYHA, New York Heart
Association; TAVR, transcatheter aortic valve replacement; TIA, transient
ischemic attack.







Abbott portico, n (%) 18 (25)
Medtronic Evolut R, n (%) 51 (72)
Edwards Sapien III, n (%) 2 (3)
Approach
Femoral, n (%) 59 (83)
Subclavian, n (%) 10 (14)
Transapical, n (%) 2 (3)
Anesthesia
General anesthesia, n (%) 29 (41)
Conscious sedation, n (%) 42 (59)
Procedural outcomes
Total duration of hospitalization, days 5 (4–7)
Duration of hospitalization in TAVR center, days 2 (2–4)
Duration of hospitalization in referring
hospital, days
3 (2–4)
Admission to ICU, n (%) 21 (30)
PVR ≥moderate, n (%) 7 (10)
Vascular complication, n (%) 8 (11)
Major, n (%) 2 (3)
Minor, n (%) 6 (8)
Bleeding complication, n (%) 8 (11)
Major, n (%) 2 (3)
Minor, n (%) 6 (8)
Stroke/TIA, n (%) 5 (7)
Conduction disturbance requiring pacemaker
implantation, n (%)
6 (8)
Conversion to open surgery, n (%) 1 (1)
30‐Day mortality, n (%) 4 (6)
COVID‐19 related outcomes
COVID‐19 testing before TAVR, n (%) 25 (35)
Positive testing (PCR and/or CT), n (%) 0
COVID‐19 testing after TAVR, n (%) 8 (11)
Positive testing (PCR and/or CT), n (%) 2 (3)
Death due to COVID‐19, n (%) 2 (3)
Note: Data are presented as median with interquartile range, or as
number (%).
Abbreviations: COVID‐19, coronavirus disease 2019; CT, computed
tomography; ICU, intensive care unit; PCR, polymerase chain reaction;
PVR, paravalvular regurgitation; TAVR, transcatheter aortic valve
replacement; TIA, transient ischemic attack.
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5 days (IQR: 4–7 days). Besides the aforementioned case of proce-
dural death, there was one patient that died 4 days after TAVR,
which was complicated by device migration, for which a second valve
prosthesis was placed. Moreover, the procedure was complicated by
a cerebrovascular accident and a local dissection of the distal as-
cending aorta, for which conservative treatment was chosen. Four
days after the TAVR procedure, the patient died after unsuccessful
resuscitation for asystolic cardiac arrest. Autopsy and postmortem
computed tomography (CT) showed a hemopericardium secondary
to a rupture of the ascending aorta. In addition to the two befor-
ementioned cases of intra‐ and postprocedural mortality, two patients
died because of respiratory failure due to PCR proven COVID‐19
pneumonia. In conclusion, a total of 4 patients (6%) died within 30 days
after TAVR. The two cases of respiratory failure due to COVID‐19
pneumonia after TAVR will be described in more detail below.
3.1 | Case descriptions of two patients with
COVID‐19 pneumonia after TAVR (Central Figure)
The first patient was a 76‐year‐old man referred to our hospital as an
outpatient with critical AS (aortic valve area [AVA] of 0.5 cm2) and
mild left ventricular dysfunction (LVEF: 40%–45%). His previous
medical history was extensive, including chronic obstructive pul-
monary disease (COPD), diabetes mellitus, multiple myocardial in-
farctions, and percutaneous coronary interventions, and quadruple
coronary artery bypass grafting 8 years before. Due to his severe
symptoms (graded as NYHA Class III–IV) with critical AS, this patient
was triaged as urgency Level 1 (i.e., TAVR preferably within 1 week).
At admission, the patient did not exhibit any COVID‐19 related
symptoms. Therefore, no COVID‐19 testing was performed before-
hand, according to protocol. Using conscious sedation, TAVR was
successfully performed using transfemoral approach, with trivial
valvular and paravalvular regurgitation. Patient was discharged the
following day to the referring hospital for further rehabilitation, and
discharged home 3 days after TAVR.
Thirteen days after the TAVR procedure (and 10 days after last
hospital stay), the patient was presented in our emergency depart-
ment with a 4‐day history of fever, fatigue and dyspnea. Chest CT
showed bilateral ground‐glass opacities and crazy paving appear-
ance, typical of COVID‐19 pneumonia.9 Subsequent PCR‐testing was
positive for COVID‐19. The patient was admitted and treated with
oxygen and chloroquine. Rapid deterioration to hypoxemic
respiratory failure warranted the initiation of invasive mechanical
ventilation. Intubation and ICU admission was declined by both
patient and family. The patient died the next morning. Regarding
contact tracing, the patient received only hospital and house visits
from two visitors. Visitor 1 exhibited loss of taste and smell (which
later progressed to symptoms of dyspnea) 3 days before the patient
displayed any COVID‐19 related symptoms (Central Figure). Visitor
2 exhibited symptoms of dyspnea 7 days after the patient's death
(12 days after the patient first exhibited COVID‐19 related symp-
toms). In both the TAVR‐center and the referring hospital, no
COVID‐19 cases were reported among the hospital personnel during
that period.
The second patient was an 85‐year‐old man who was referred to
our hospital as an outpatient with symptomatic, severe aortic
stenosis (AVA 0.8 cm2) and preserved LVEF of more than 50%. His
medical history included permanent atrial fibrillation and bilateral
hip replacement. His symptoms were graded as NYHA II, with
dyspnea on exertion and fatigue being his main symptoms. This
patient was triaged as urgency Level 2.
Using conscious sedation, TAVR was successfully performed
through transfemoral approach, with no valvular and paravalvular re-
gurgitation. However, the procedure was complicated by bleeding of
the right femoral artery due to unsuccessful placement of the closure
device, necessitating surgical repair under general anesthesia and
admission to the ICU. The same evening of the TAVR procedure, the
patient was transferred to the CCU. The patient was discharged to
the cardiology ward of the referring hospital for further rehabilitation
the following day, and discharged home 4 days after TAVR.
Seven days after discharge (and 11 days after TAVR), the patient
presented to the emergency department with a 2‐day history of
fever, dyspnea and orthopnea. Chest CT showed bilateral ground‐
glass opacities and possible peribronchial infection in the left lower
lobe. Subsequent PCR testing was positive for COVID‐19. Patient
was admitted to the COVID‐19 ward and died 5 days later due to
respiratory failure.
Contact tracing revealed hospital visits from only one visitor for
this patient. This person exhibited COVID‐19 related symptoms after
the patient's readmission to the hospital (4 days after the patient
exhibited symptoms), with PCR confirming COVID‐19 five days after
the patient's death. Other visitors outside the hospital never
exhibited any COVID‐19 related symptoms. In both the TAVR‐center
and the referring hospital, no COVID‐19 cases were reported among
the hospital personnel during that period.
4 | DISCUSSION
In our single‐institutional cohort study with 71 patients undergoing
TAVR during the COVID‐19 crisis, there were two patients (3%) with
proven COVID‐19 pneumonia a few days after TAVR, both resulting
in death approximately 2 weeks after TAVR (and 11–12 days after
last hospital stay).
Although it is clear that TAVR cannot be postponed for a pro-
longed period in patients with symptomatic severe or critical AS, the
risk of deferment of the procedure has to be balanced against the
dangers of COVID‐19 transmission before and after the procedure
and associated morbidity and mortality in this vulnerable population.
For inpatients who cannot be discharged due to medical reasons, we
believe it is rational to perform the necessary procedures during the
COVID‐19 crisis, as recommended by the previously mentioned
ACC/SCAI consensus statement.5 However, for outpatients, there
will be need for additional hospital admissions and hospital stay,
potentially increasing their risks of COVID‐19 exposure. It has been
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well documented that the case‐fatality rate is significantly higher in
elderly patients with COVID‐19 pneumonia (8%–13% for age 70–79
years, 15%–20% for age ≥80 years).10 Furthermore, the TAVR po-
pulation is typically frail with important comorbid diseases. In our
study population, 100% had coronary or peripheral artery disease,
37% had diabetes mellitus, 20% had cerebrovascular disorders, 21%
had COPD, all which are known risk factors for increased COVID‐19
related morbidity and mortality.11,12 In addition, TAVR might lead to
significant inflammatory modulation,13,14 as with most surgical and
interventional procedures,15 leading to an exacerbated course of a
COVID‐19 infection (Figure 1).
At this moment, the risks of nosocomial COVID‐19 exposure
remain unknown and are currently under investigation
(NCT04290780). Nevertheless, cases of nosocomial COVID‐19
transmission are factual and have already been reported.16,17 In
our study, two patients with COVID‐19 pneumonia died respectively
14 and 16 days after TAVR. Initial COVID‐19 symptoms started 5–6
days after discharge to home, and 9 days after TAVR procedure.
Considering the reported median incubation period of 5 days be-
tween patients showing symptoms and initial COVID‐19 exposure,18
the patients can either have acquired COVID‐19 during hospital stay
or at home. The exact source of COVID‐19 transmission remains
uncertain. In our own center and the referring hospitals where the
two patients were admitted, no COVID‐19 cases have been reported
among the hospital personnel during that time period. Conversely,
among the visitors of these two patients, one exhibited anosmia and
ageusia before the patient demonstrated COVID‐19 related symp-
toms (Central Figure). Although visiting restrictions were already
widely implemented in all hospitals in the Netherlands and world-
wide, anosmia and ageusia were possible less well recognized
COVID‐19 related symptoms in the general public at that time.
Nevertheless, it might be advisable to encourage even stricter vis-
iting guidelines for the patients who are at high risk for severe illness
from COVID‐19, including these elderly patients with multiple co-
morbid diseases undergoing TAVR.
There are several limitations to our current study. First of all,
only a minority of patients underwent COVID‐19 testing by PCR
before TAVR (35%). Therefore, there is a possibility that the two
COVID‐19 cases in our series were already COVID‐19 positive be-
fore their hospital admission and before TAVR. However, considering
the time interval between hospital admission and onset of symptoms
(10 days in both patients), it is not likely these patients would have
tested positive before TAVR. Also, only eight patients underwent
PCR testing after TAVR, thereby possibly underestimating the
number of postprocedural COVID‐19 cases by neglecting the
asymptomatic patients.
Second, the study population is too small to justify definitive
conclusions regarding risks and route of COVID‐19 transmission and
the additional morbidity and mortality risks caused by COVID‐19
infection. Nevertheless, to the best of our knowledge, this is the first
study reporting data on feasibility and safety outcomes of TAVR
procedures during the COVID‐19 pandemic. Data from large, pre-
ferably multicentered or nationwide registries are needed to better
clarify these risks.
What are the implications of our findings? First of all, a continued
TAVR program during this pandemic is feasible, despite restricted
hospital resources and minimal ICU capacity. With a strategy focused
on TAVR through conscious sedation when feasible, ICU dependency
can be diminished. In our study, 61% of patients were assessed be-
forehand as feasible to undergo TAVR using conscious sedation, with
one patient requiring conversion to general anesthesia due to a vascular
complication necessitating surgical repair. This rate is similar to the
recently reported proportion of 64% undergoing transfemoral TAVR
under conscious sedation among 120,080 patients in the TVT
Registry.19 Conversely, while a continued TAVR program is feasible on
an organizational level, we want to highlight that the continuation of
F IGURE 1 Central Figure : timeline of patients with COVID‐19 pneumonia after TAVR (accompanied by data on contact tracing). COVID‐19,
coronavirus disease 2019; PCR, polymerase chain reaction; TAVR, transcatheter aortic valve replacement
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non‐COVID‐19 related care during this unprecedented pandemic in
modern times is not without risks for the patient. This is especially true
regarding TAVR for a particularly vulnerable, elderly population. During
the study period, there was still active COVID‐19 transmission in the
community. Through a combination of containment and mitigation
activities, the number of new COVID‐19 cases are stabilizing or on the
decline worldwide.20 The overall prevalence and transmission risks of
COVID‐19 in the general population may now be much lower. Conse-
quently, focus has already been shifting towards “post‐COVID‐19”
reactivation of surgical and interventional programs.21 However,
concern has also been raised regarding potential resurgence and
possible additional COVID‐19 waves.22 Therefore, depending on
the actual regional COVID‐19 prevalence and hospitalization
rates, COVID‐19 related concerns will remain. As such, COVID‐19
associated risks of in‐hospital treatments with accompanied
COVID‐19 transmission dangers should be an important focus of
future reports, and these risks should be balanced against the
hazards of deferred interventions for the cardiovascular patient
on an individual basis. We expect this will be of continued concern
for the foreseeable future.
5 | CONCLUSION
In conclusion, we have reported the first case series of TAVR proce-
dures performed during the COVID‐19 pandemic. Two cases of COVID‐
19 pneumonia were diagnosed, with an unknown source of transmis-
sion soon after the intervention, both leading to mortality within
2 weeks after hospital discharge. We eagerly await subsequent reports
from large registries to more accurately clarify the risks and source of
COVID‐19 transmission after cardiac interventions, as well as the
accompanied additional risks caused by COVID‐19 related morbidity
and mortality. Until then, the complex balancing act of weighing the
risks of health loss due to COVID‐19 against the risks of postponing a
potentially life‐saving procedure remains a challenge for the clinician
and the patient, and should be part of shared‐decision making.
Furthermore, strict visiting policies should be considered in this vul-
nerable population after TAVR, both during and after hospital stay, with
education of potential visitors of all COVID‐19 related symptoms.
CONFLICT OF INTERESTS
The authors declare that there are no conflict of interests.
ORCID
Maxim J.P. Rooijakkers https://orcid.org/0000-0002-6815-7667
REFERENCES
1. Zhu N, Zhang D, Wang W, et al. China novel coronavirus in-
vestigating and research team. N Engl J Med. 2020;382:727‐733.
2. Søreideøreide K, Hallet J, Matthews JB, et al. Immediate and long‐
term impact of the COVID‐19 pandemic on delivery of surgical
services. Br J Surg. 2020;107:1250–1261. https://doi.org/10.1002/
bjs.11670
3. Gaudino M, Chikwe J, Hameed I, Robinson NB, Fremes SE,
Ruel M. Response of cardiac surgery units to COVID‐19: an
internationally‐based quantitative survey. Circulation. 2020;142:
300‐302.
4. Malaisrie SC, McDonald E, Kruse J, et al. Mortality while waiting for
aortic valve replacement. Ann Thorac Surg. 2014;98:1564‐1570.
5. Shah PB, Welt FGP, Mahmud E, et al. from the American College
of Cardiology (ACC) and the Society for Cardiovascular Angio-
graphy and Interventions (SCAI). Triage considerations for
patients referred for structural heart disease intervention during
the coronavirus disease 2019 (COVID‐19) pandemic: an ACC
/SCAI Consensus Statement. JACC Cardiovasc Interv. 2020;13:
1484‐1488.
6. Current information about COVID‐19 (novel coronavirus).
National Institute for Public Health and the Environment.
Available at: https://www.rivm.nl/en/novel-coronavirus-covid-19/
current-information. Accessed September 17, 2020.
7. Tostmann A, Bradley J, Bousema T, et al. Strong associations and
moderate predictive value of early symptoms for SARS‐CoV‐2 test
positivity among healthcare workers, The Netherlands, March 2020.
Euro Surveill. 2020;25:2000508.
8. Kappeteinappetein AP, Head SJ, Généreux P, et al. Updated stan-
dardized endpoint definitions for transcatheter aortic valve im-
plantation: the Valve Academic Research Consortium‐2 Consensus
Document. Eur Heart J. 2012;33:2403‐2418.
9. Ye Z, Zhang Y, Wang Y, Huang Z, Song B. Chest CT manifestations
of new coronavirus disease 2019 (COVID‐19): a pictorial review.
Eur Radiol. 2020;30:4381‐4389.
10. Onder G, Rezza G, Brusaferro S. Case‐fatality rate and character-
istics of patients dying in relation to COVID‐19 in Italy. JAMA. 2020;
323:1775‐1776.
11. Guan W, Liang W, Zhao Y, et al. China medical treatment expert
group for COVID‐19. Comorbidity and its impact on 1590 patients
with COVID‐19 in China: a nationwide analysis. Eur Respir J. 2020;
55:2000547.
12. Du RH, Liang LR, Yang CQ, et al. Predictors of mortality for patients
with COVID‐19 pneumonia caused by SARS‐CoV‐2: a prospective
cohort study. Eur Respir J. 2020;55:2000524.
13. Sexton TR, Wallace EL, Chen A, et al. Thromboinflammatory response
and predictors of outcomes in patients undergoing transcatheter aortic
valve replacement. J Thromb Thrombolysis. 2016;41:384‐393.
14. Sexton T, Alkhasova M, de Beer M, Lynch D, Smyth S. Changes in
thromboinflammatory profiles across the generations of transcath-
eter aortic heart valves. J Thromb Thrombolysis. 2019;47:174‐178.
15. Uhle F, Castrup C, Necaev AM, et al. Inflammation and its con-
sequences after surgical versus transcatheter aortic valve replace-
ment. Artif Organs. 2018;42:E1‐E12.
16. Li Y, Peng S, Li L, et al. Clinical and transmission characteristics of
COVID‐19—a retrospective study of 25 cases from a single thoracic
surgery department. Curr Med Sci. 2020;40:295‐300.
17. Schwierzeck V, König JC, Kühn J, et al. First reported nosocomial
outbreak of severe acute respiratory syndrome coronavirus 2
(SARS‐CoV‐2) in a pediatric dialysis unit [published online ahead of
print April 27, 2020]. Clin Infect Dis. 2020. https://doi.org/10.1093/
cid/ciaa491
18. Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus
disease 2019 (COVID‐19) from publicly reported confirmed cases:
estimation and application. Ann Intern Med. 2020;72:577‐582.
19. Butala NM, Chung M, Secemsky EA, et al. Conscious sedation versus
general anesthesia for transcatheter aortic valve replacement:
variation in practice and outcomes. J Am Coll Cardiol Intv. 2020;13:
1277‐1287.
20. WHO Coronavirus Disease (COVID‐19) Dashboard. Available at:
https://covid19.who.int/. Accessed July 22, 2020.
54 | ROOIJAKKERS ET AL.
21. Joint Statement: Roadmap for Resuming Elective Surgery after
COVID‐19 Pandemic. Online April 17, 2020. Available at: https://
www.facs.org/covid-19/clinical-guidance/roadmap-elective-surgery.
Accessed July 22, 2020.
22. Kissler SM, Tedijanto C, Goldstein E, Grad YH, Lipsitch M. Projecting
the transmission dynamics of SARS‐CoV‐2 through the postpan-
demic period. Science. 2020;368:860‐868.
How to cite this article: Rooijakkers MJ, Li WW, Wollersheim
LW, et al. Transcatheter aortic valve replacement during the
COVID‐19 pandemic—A Dutch single‐center analysis. J Card
Surg. 2021;36:48–55. https://doi.org/10.1111/jocs.15123
ROOIJAKKERS ET AL. | 55
